Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care

Chair, April W. Armstrong, MD, MPH, discusses psoriasis in this CME/MOC/NCPD/AAPA/IPCE activity titled “Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3IdlHLP. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.

1. Elevating Psoriasis and Comorbidity
Management With TYK2 Inhibition

Achieving and Sustaining Outcomes
to Transform Care

April W. Armstrong, MD, MPH

Professor and Chief of Dermatology
University of California, Los Angeles (UCLA)
Los Angeles, California

Go online to access full CME/MOC/NCPD/AAPA/IPCE information, including faculty disclosures.

Copyright

2000-2025, PeerView

2. Our Goals for Today

Enhance your knowledge of pathophysiology driving
PsO and related comorbidities

Prepare you to identify ideal patient candidates
for TYK2 inhibition in psoriatic disease management

Provide guidance on best strategies in developing
team-based, individualized PsO care plans

Copyright © 2000-2025, Peerview

3. Can We Improve the Treatment Experience and
Outcomes on the Psoriatic Disease Spectrum?

25, PeerView

4. Meet Jeff: 36-Year-Old Man With New Complaints of a Rash?

+ HPI: Has noticed red, flaky plaques
on his arm for the past 5 months;
has never been diagnosed with
PsO before

+ Relevant PE findings
— BSA:~11%

— Well-demarcated, erythematous
plaques with moderate scaling
and flaking

Images courtesy of April Armstrong, MD.

PeerView.com/SMF827

U How do Jeff's symptoms
align with the clinical
presentation of PsO?

Does he meet criteria

for diagnosis? If not,
what additional
information is needed?

If diagnosed with PsO,
how would you classify
the severity?

PeerView

Copyright © 2000-2025, PeerView

5. Psoriasis Affects the Whole Person!

Psoriatic arthritis affects
approximately 30% of people
who have psoriasis

+ Increasing evidence supports the
recognition of psoria; a multisystem
chronic inflammatory disorder with
multiple associated comorbidities

People who treat their psoriasis
y can also lower their risk
of other comorbidities

1. Ets CA ol a Am Acad Dermatol 201980:1073-1113 PeerView

PeerView.com/SMF827 Copyright © 2000-2025, Peerview

6. Classifying Psoriasis Severi

Mild

Psoriasis
severity is often
categorized as

Guided by measurements such as body surface area (BSA),

Physician's Global Assessment (PGA),
and the Psoriasis Area and Severity Index (PASI)

1. Svober Beta. J Am Acad Darmetot 2020 82:117-122. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

7. Delphi Consensus Fr:

Candidates for
systemic therapy
or phototherapy

Candidates
for topical
therapy

PD

1. Saber B etal. J Am Acad Dermatol 2020.82:117-122.

PeerView.com/SMF827

Recategorization of Psoriasis Se:
e Internatio:

I Psoriasis Council!

Meet at least one of the following criteria
1.BSA >10%

2. Disease involving special areas

3. Failure of topical therapy

For clarity and brevity, the term
“special areas" was used in the
severity statement to refer to

psoriasis affecting more impactful
sites such as the face, palms, soles,
genitalia, scalp, or nails

PeerView

Copyright © 2000-2025, PeerView

8. Many Patients With Mild to Moderate Psoriasis

Have Affected Special Areas!

+ On average, patients had two affected sensitive areas, despite 60% currently having mild psoriasis

100
so 73

ss

E so
60 | 204. o

2 6
“ 3
pal 2 2 a Ed
a
‘ ‘

2 18,5 ‘ll 1s, ut
o ol

Scalp Face

Moon Mines A lf severe esa cto)

100 4 C0 100 100

3 3

Proportion of Patients, %.
Proportion of Patients, %.

8

2
1
12

Genitals Nails Soles. Palms 21 Sensitive Area" 22 Sensitive Areas — 23 Sensitive Areas

*.Amsirong AW eta. Dermatlogy 2023230621-64. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

9. Revisiting Jeff: 36-Year-Old Man With New Complaints of a Rash?

+ HPI: Red, flaky plaques on his arm
for the past 5 months; has never
been diagnosed with PsO before

+ Objective findings

— BSA; moderately thick plaques
on ~11% of body

~ Well-demarcated, erythematous
plaques with moderate scaling
and flaking

= PGA: 3

- DLAI: 13

+ Images courtesy of Apa Armstrong, MD.

PeerView.com/SMF827

Q How do Jeff's
symptoms align
with the clinical
presentation of PsO?

Does he meet criteria
for diagnosis?

If diagnosed with PsO,
how would you classify
the severity?

PeerView

Copyright © 2000-2025, Peerview

10. Addressing Unmet Needs and Accounting for Patient
Preferences in Psoriatic Disease Management!

There remains a critical need for effective and safe oral and topical treatments, as well as

personalized approaches to slow disease progression and reduce the burden of comorbidities

Topical therapies

Oral therapies

Patient
Preferences

1. Schlapbach Got al Alorgy Gin imanol 2022:50091.6740.00306-4. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

11. Uncovering the Molecular Drivers
of Psoriasis and Its Comorbidities

100-2025, PeerView

12. 1 Amarong AW etal. AMA. 2020;3281948-1960 PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

13. {Baker KF eta. Ann Rheum Di. 201877175-187. 2. Go Ket al ACRIARHP 2016. Aosta HL. i
3 ang Let Bal Chem. 2008283 28066-28073, 4. X et a J Biol Chom. 2002:277:14020-1408. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

14. 1. Baker KF et al. Ann Rheum Dis. 2018:77:175-187. 2. nk bir ACRIARHP 2016. Abstract 11L. Jiew
3 ang Let al la Chem 2008283 28066-28073. 4. X Jet a J Biol Chom, 2002:277 14020-14050. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

15. The Role of TYK2 in the Pathogenesis of Psoriasis!

© Typetirnap jes
U Extraceltutar us
11.23 TYR2 war
== Ls ,
e E o Keratnoeye
[stars EN
— Cytoplasm À
IL-17 promotes the |
T-cell differentiation eS proliferation of keratinocytes y
is associated with à and epidermal hyperplasia
the secretion of IL-23, Gene transcription
pe Development
= eg, mDC Nucleus 7 Thi? of plaques
IL-23/Th17 axis in PSO and PSA
2 Type 1 EN signaling can lso induce formation of STATA/ hamodimars
4. Blawat A, Chisco A. Cin Rav Allergy Immunol 2018:55979:00, 2. Chen K tal J Auteimmun. 2017:83:1-11. 3. Gonciaz Me al Immunetharapy.
2021:13:1135-1150,4, Hawkes JE at al. JAlery Cin Immunol 2017:140:645 63,5. D Cesare A et a J Invest Comma. 2009129: 1339-1380.
8 Goslun Metal. Pharmacol Ras. 20176 -8 1. Dolgoo GM, Val DAA. JARSTAT. 2013. 623060)

PeerView.com/SMF827

Copyright © 2000-2025, PeerView

PeerView

16. TYK2 and JAK1/2/3 Are Structurally Different From Each Othe!

The regulatory, or pseudokinase, domains of TYK2, JAK1, JAK2, and JAK3 are different from each other

JAK1 JAK2 JAK3

Active (ATP-binding) domain: similar across family members

+ Typically, JAK1, JAK2, and JAK3 inhibitors bind to the ATP-binding site of the catalytic domain of the
JAK, resulting in competitive inhibition of the kinase; however, the ATP-binding domain shows high
sequence homology among the different JAKs, reducing the selectivity of such a therapeutic approach

+ Deucravacitinib, on the other hand, binds to the regulatory domain and thus inhibits TYK2 via an
allosteric mechanism

4. Tori Jet lJ Bie! Chem. 2015.20:11081-11074 PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

17. Selectivity Profile of the TYK2 Inhibitor Deucravacitinib

Compared With JAK1/2/3 Inhibitors’

Simulated Daily Average Percent Inhibition by Deucravacitinib and JAK1/2/3 Inhibitors.

Make activity yak activity Bl TYK2 activity

I 1
100 94 | I
I 83 I
* 80 & 70 | 69
60
2 60 | 1
2 | | =
2 43
= 40 I |
= | |
5
& 20 |
01 o 0 104 0.5 4 À
SmgBID 10mgBID 15mgQD 30mgQD 2mgQD 4mgQD 6mgQD 12mgQDd
Tofacitinib Upadacitinib Baricitinib Deucravacitinib
PeerView

1. Chimalakonda A e al. Dermatol Thor (Hoidel).2021:11:1763-1778.

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

18. Pulling the Pearls From the Data

The Expanding Evidence Base
on TYK2 Inhibitors in Psoriatic Disease

Copyright © 2000-2025, PeerView

19. Revisiting Jeff: 36-Year-Old Man With Newly Diagnosed PsO?

+ HPI: Has noticed plaques for the
past 5 months; has never been
diagnosed with PsO before; has a
preference for oral treatment

+ Objective findings
— BSA: moderately thick plaques

on ~11% of body
- PGA:3
- DLAI: 13

+ Labs: IGRA (negative), LFTs WNL,
hep B and C serologies (negative)

+ Images courtesy of Apel Armstrong, MD.

PeerView.com/SMF827

Q Is Jeff a good candidate
for oral therapy?

Q Ifso, which agents
would you consider and
discuss with him?

PeerView

Copyright © 2000-2025, PeerView

20. inib, First-in-Class TYK2 Inhibitor: Primary Efficacy

Outcomes in Two Global Phase 3 Studies!

PASI 75 Response at Week 16 (Coprimary Endpoint) and Through Week 24 (NRI) in Two Global Phase 3 Studies

POETYK PSO-1 POETYK PSO-2

Placebo (n = 166) | Primary endpoint 100
Deucravaciinib (n = 332) 1
Apremilast (n= 168)

Primary endpoint

Deucravacitinib

i
1
6 mg QD |

Doucravaciinio
= [3]

Patients, %
8

3
3

Apremilast
30 mg BID

o 4 8 2 16 2 24 o 4 8 12 16 20 24
Time, week Time, week

+ 82.5% (PSO-1) and 81.4% (PSO-2) of deucravacitinib patients who achieved PASI 75 at week 24, and continued
treatment, maintained response at week 52

2 P<. 0001 ve aco,» P< 0001 vs aromas. P= 0008 vs apra i
Y Armerong AW etal AAD VAX 2021. Lat bres mens PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

21. PASI 75 Response Rates in Patients on Continuous

Deucravacitinib Treatment Durable Through 5 Years!

Analysis method: @As observed @TFR @mNRI

Start of
LTE
¿io n 01.0%.
g 80
é 60
2
E 40
8 20
8
æ 0 r T — 7 7 >
0 8 16 24 32 40 52 60 68 76 88 100 112 124 136 148 160 172 184 196 208 220 232 244 256
Time, wk
No ahi
Mei $13 510-605 $00 6 sin ao ae HOD do de 4m ae si %é a a
TER EEE ae An A7 E 0 6 si Sn 2
EEE
‘PNR mos nonresponders imputation. TER: aiment a n
‘himsvong AW et al Water cal Damatigy Conference 2025 PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

22. Deucravacitinib AEs of Interest (Integrated): Weeks 0-521

MÁ pracebo Mf Deucravacitinib J Apremilast

Estimated Incidence Rate
(95% Cl) per 100 PY
nos oo.

= oe
E 828
E

2

2
Malignancies | Serious
(non-NMSC) | infections | Herpes zoster SE (PE + DVT) w

DEUC | HE

APR HH

HE

ES

PEO
DEUC Hb
APR | 4

Deuc | HK

NMSC.

+ None of the serious infections with deucravacitinib led to discontinuation

+ No cases of herpes zoster with deucravacitinib were serious or led to discontinuation

+ No TB events and no opportunistic systemic infections were reported with deucravacitinib

+ There were two cases of VTE in the deucravacitinib group; neither was attributed to the drug by investigator (EAIR: 0.21 per 100 PY)

1. Amsirong A et al. AAD VMX 2021. Oral presentation. 2. Warren R eta. San Diego Dermatology Symposium 2022. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

23. Additional Selective TYK2 Inh

+ Zasocitinib and ESK-001 are investigational, selective TYK2 inhibitors being studied for the
treatment of psoriatic diseases

+ Both compounds inhibit TYK2 by targeting its regulatory (pseudokinase or allosteric) domain

Age! O Trial Status A Trial Status
Zasocitinib ° Soe ae ea stp + Positive phase 2b results
NDI-034858; ‘ ase 3 trials evaluating zasocitinil 3 |
QU vs placebo, apremilast, and pre Sulz ER
deucravacitinib ongoing going
Positive phase 2 results
ESK-001

Phase 3 ONWARD trial series ongoing

1. Mipsis gov. 2. Mari. Dermatol Ther (Hee). 2023.13:17-6. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

24. ib: Efficacy and Safety in PsO1?

4) Placebo (n = 52) À Zasocitinib, 5 mgid (n = 52) | Zasocitinib, 30 mg/d (n = 52)
© Zasocinib, 2 mgid(n= 60) — W Zasocitnib, 15 mg/d (n = 53)

PASI75 PASI 90 + Most frequent TEAES
- COVID-19
100 100 = es
~ Diarrhea
; 80 im x 00
om TEAES were more
Es Ë 60 e frequent with zasocitinib
8 4 a 2 40 ae (63%-62%) than placebo
5 (44%) but were generally
& 3 i mild, and no serious
22 10% g 2 = safety signals were
es observed
o 0
0.2.4 8 12 0 2 4 8 12
Time Since Treatment Start, wk Time Since Treatment Start, wk
+. Amatong AW et JA Dana 200410 406610142. sat gov NOTARE. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

25. ESK-001: Efficacy and Safety in PsO at Week 16:

STRIDE Phase 2 Trial!

PASI 75 PASI 90
100 End of treatment 100 End of treatment
9 1 90 '
& 80 & 80
70 2 70
Eo En
a 50 g 50
5 40 5 40
& 30 & 30
E 20 22
10 10
o 0 4
0 124 8 2 16 0124 8 2 16
Time, wk Time, wk
-0- Placebo (n = 38) ©- 20mg QD (n=36) — ~@ 40 mg QD (n= 39)

10mgQD(n=36) -@- 20mgBID(n=39) -0-40m9BID(n=39)

2 Ps 0001." Ps .008.°Ps.08.
4. Blsuvok À at a! J Am Acad Dermatol 2025:50190-9622(25/02465-1.

PeerView.com/SMF827

Most frequent TEAES
= Headache

- URTI

= Nasopharyngitis.

ESK-001 was generally

safe and well-tolerated
over 12 wk of treatment,
with a low discontinuation

rate (2.6%) and no

dose-limiting safety
findings or deaths

PeerView

Copyright © 2000-2025, PeerView

26. Revisiting Jeff: 36-Year-Old Man With Newly Diagnosed PsO?

+ HPI: Has noticed plaques for the
past 5 months; has never been
diagnosed with PsO before

+ Objective findings
— BSA: moderately thick plaques

on ~11% of body
- PGA:3
- DLAI: 13

+ Labs: IGRA (negative), LFTs WNL,
hep Band C serologies (negative)

+ Images courtesy o Apr Armstrong, MD.

PeerView.com/SMF827

Q How do available data
surrounding TYK2

inhibition apply to his
case?

Is he a good candidate
for TYK2 inhibition?

PeerView

Copyright © 2000-2025, PeerView

27. eturning to Jeff: 5 Months After Treatment?

Before

+ images courtesy of Apr Armstrong. MD. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

28. Meet Tony: 46-Year-Old Man With PsO

and Scalp Symptoms on Apremilast!

+ HPI
- 12-year history of PsO; not well controlled
on apremilast (ongoing GI side effects)
— Most bothered by scalp involvement
= Endorses persistent itching, scalp
discomfort, sleep disturbances, and

embarrassment
+ Objective findings
— BSA: moderately thick plaques on ~13%
of body
= PGA:4

- DLAI: 9

1. Dufin KC ot al. EADV 2025. Poster P1216,

PeerView.com/SMF827

Are there data to
support the use
of TYK2 inhibition in

scalp PsO?

How does TYK2
inhibition compare
with other therapies?

PeerView

Copyright © 2000-2025, PeerView

29. POETYK PSO-1 and PSO-2: Scalp-Specific PGA (ss-PGA) 0/1

Responses? Through Week 161?

In both trials, significantly more patients receiving deucravacitinib vs placebo and vs apremilast achieved ss-PGA 0/1 at week 16
+ Efficacy was significantly greater with deucravacitinib vs placebo by week 2 and vs apremilast by week 8

POETYK PSO-1 POETYK PSO-2

100 100

EN 90

40 Placebo (n = 121) on Placebo (n= 173)
Deucravacitinib (n = 208) Deucravacitnib (n = 305)

704 Apremilast (n= 110) 70 Apremilast (n = 166)

es
60 60 %

50

de Deucravacitinib 6 mg QD

de y
4 Deucravacitinib 6 mg QD

ss-PGA 0/1 Response Rate, %
ss-PGA 0/1 Response Rate, %

do 20 37
= Apremilast 30 mg BID 20 Apremilast 30 mg BID
20 174 20 173
10 10
0 . 0
012 4 8 12 16
Time, weeks

«Included patents wih a baseline ss-PGA score 23.» Missing data were imputed wih nonresponderimputaton
<P< 01 vs placebo, +P <.05 vs apremlast.»P <.0001 vs placebo. P< 0001 vs apremilast. PeerView
1 Armsirong AW et al, AAD VIX 2021. Lat breaker.

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

30. POETYK PSO-1:

ss-PGA 0/1 Responses Through Week 52 (PSO

ss-PGA 0/1 responses at week 16 were maintained through week 52 with continuous deucravacitinib treatment

+ Patients who switched from placebo to deucravacitinib at week 16 achieved comparable ss-PGA 0/1 responses
at week 52 to those who received continuous deucravacitinib treatment

Primary endpoint

100
90
80
70

60 Deucravacitinib 656
u (n= 209)
40

Placebo
(n= 121)

30
20
10

Response Rate, %

0 4 8 12 16 20 24 28 32 36 40 44 48 52
Time, weeks

+ The majority (88.9%) of patients had scalp involvement at baseline; >55% of patients had moderate to severe scalp psoriasis (ss-PGA 23)
at baseline and were evaluated for ss-PGA 0/1 responses

‘Missing data wore imputod with nonrosponder imputation.
1-Armetrong AW eta. AAD VIX 2021. Late breaker.

PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

31. Deucravacitinib Effects on Scalp PSO: PSORIATYK SCALP"

Ss-PGA 0/1 Response at Wk 16 PSSI 90 Response at Wk 16 Scalp-Specific Itch NRS Response
200 Primary Endpoint 100) Key Secondary Endpoint (24-point Reduction) at Wk 16
100) Exploratory Secondary Endpoint

Se So 8 so

É P< 0001 q

El eo | a 3

20 20 —— 2 60

¿ g £

Es 2 Ev

a lo: i

B 20 & 20 3 20

2 & [3

o ee 7

Placebo Devcravacitinib Placebo Deucravacitinib Placebo Deucravactinib
nen (n= 103) (n= 51) (n= 103) (n=51) (n= 103)

Deucravacitinib showed robust efficacy and a consistent safety profile in moderate to severe scalp PsO,
including patients with limited BSA (23%), achieving superiority over placebo across all endpoints

1. Duin KC tal. Fall inca! Dermatology Conference 2024. Poster. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

32. Following Up With Tony Abo

Symptoms on Apremilast!

Uncontrolled PsO and Scalp

+ HPI
= 12-year history of PsO; not well controlled
on apremilast (reports ongoing GI
side effects)
- Most bothered by scalp involvement
— Endorses persistent itching, scalp

discomfort, sleep disturbances,
and embarrassment
+ Objective findings
— BSA: moderately thick plaques on ~13%
of body
- PGA:4
= DLAI:9

1. Dufin KC ota. EADV 2025. Poster P1216

PeerView.com/SMF827

O Would you consider
TYK2 inhibition
for Tony?

How would you
navigate therapy
selection and shared
decision-making?

PeerView

Copyright © 2000-2025, PeerView

33. Before

4. Dutin KC etal. EADV 2025, Poster P1216, PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

34. Meet Sharon: 56-Year-Old Woman With Long-Standing PsO

and New Onset PsA’

+ CC: 6-month history of morning stiffness
in fingers and ankles
+ HPI
- 23-year history of PsO; managed with
methotrexate 15 mg weekly and
occasional clobetasol ointment
+ Relevant PE findings
— Skin: erythematous plaques ~10% BSA
Nails: pitting, ridging, mild onycholysis
— Joints: swelling and tenderness bilaterally
— Enthesitis at Achilles bilaterally
No dactylitis

O Are there data to support the
use of TYK2 inhibition in PsA?

PeerView

1. kumi eta. J Cutan Immuno! Alorgy.2024.7:13.

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

35. Psoriasis and Psoriatic Arthritis Have Shared Pathophysiology’

e
+@ ne aie

E AT

Development of PA
PeerView
Copyright © 2000-2025, PeerView

1. Loo BW etal. int J Mot Sci. 2023:24:11662.

PeerView.com/SMF827

36. Deucravacitinib Efficacy at Weeks 16 and 52
Phase 3 POETYK-PsA Trial!

Mrs A A

ACR 20 ACR 50 ACR70

qa 5 ts
5 a nl a e
Lo mlomtiibvo o
ds © 40 À (95% C1,0.9-9.4)
$ pan
i. à > .
i. a BERN.

— ome rom vn

Deucravacitinib demonstrated superior and sustained efficacy across musculoskeletal,
dermatologic, and QOL endpoints in adults with active PsA through 52 weeks

1. MoaseP ot al. Ana Rhoum Dis 202524 84.85,

PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

37. ib—Phase 2b Study: Efficacy in PsA’
ACR Responses at Week 12
As Usure én co (0=71)

Aa Moine 15mg 00 (a =75) zen 50 mg 00 (n=72)
[3]
E 80
= + 4
2 60
x
©
2 40 oo.
5
2
i 20

0 r

ACR20 ACR50 ACR70
‘Pita tal Ann Roum Di. 2028:8000-4967(25 01046 PeerView

PeerView.com/SMF827

Copyright © 2000-2025, Peerview

38. Returning to Sh

+ CC: 6-month history of morning stiffness
in fingers and ankles
+ HPI
— 23-year history of PsO; managed with
methotrexate 15 mg weekly and
occasional clobetasol ointment
+ Relevant PE findings
— Skin: erythematous plaques ~10% BSA
Nails: pitting, ridging, mild onycholysis
— Joints: swelling and tenderness bilaterally
— Enthesitis at Achilles bilaterally
No dactylitis

O What would you consider in choosing
an agent with PsO and PsA efficacy?

Q How would you collaborate with the
interprofessional team?

1. huni et J Cun men Ary. 024.7: PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

39. Revisiting Sharon After Deucravacitinib Treatment!

48 Weeks After
Deucravacitinib

Before

1. huni et J Cuan mano Ary. 024.71. PeerView

PeerView.com/SMF827 Copyrigh

40. Treatmen!

2 Years After

Before Deucravacitinib
Bone erosion in Bone erosion
right third distal disappeared
interphalangeal 2 years after
joint at baseline treatment

[View

1. ui Net al. J Cutan Immunol Alorgy. 2024,7:1.

Copyright © 2000-2025, PeerView

41. Advantages of TYK2 Inhibitors C ntly Approved for Psoriasis’?

QQARQARARAR

No boxed warning

rable (low rates of headache, nausea, and diarrhea)

Efficacious (superi

Similar safety profile after 5 years vs 1 year of treatment in clinical trials

No lab tests other than TB required prior to therapy initiation

‘Superior drug clearance vs other therapeutics

Impact on comorbidities (promising results in PsA, lupus, and other IMIDs)

Oral therapeutic option for patients Could be considered a first-Iine agent since failure of other therapies is not
who are candidates required: it should not be limited to this since at least one third of the POETYK
for systemic or phototherapy PSO-1 and POETYK PSO-2 study population had prior biologic exposure

1. Atduoimuia A. Gooderham MU. Expat Rov Cin Imunol. 2022:18:185-187 few
2 Sap (dovcrvactn) Preserbng infomation, hips aww acoessdat 6a gowdrogstss_docetabe 2022214958: 0000 pa PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

42. Deucravacitinib: Clinical Snapshot!

FDA approved 6 mg
FEREI ‘once daily oral m
[8888] for moderate to severe

plaque psoriasis in adults

No tests required
prior to initiation other

than TB evaluation

Evaluate liver enzymes at
baseline and thereafter in
patients with known or

ed liver disease

No known
drug-drug interactions

1. Solyktu(doucravacinb) Prescribing Information, tps www acoessdata Ida. govdrupsatida_docsfabel2022/214958s0001L pd. PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

43. Therapy

Previous Considerations
treatment for choosing
response an agent

PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

44. Ideal for systemic-naive patients

Suitable for those with more moderate forms of plaque psoriasis

Effective for high-impact areas such as the scalp

Preferred for patients who desire an oral treatment

Recent results from the phase 3b/4 PSORIATYK SCALP study
showed that more than three times as many patients achieved
ss-PGA 0/1 with deucravacitinib as did those on placebo
(48.5% vs 13.7%; P < .0001) at 16 weeks, meeting the primary endpoint

1. LebwohlM ta: EADV 2024, Poster FCD4.07 PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

45. TB evaluation

in everyone E

Prior to

In patients with known initiation

or suspected liver
disease, check

baseline LFTs and

hepatitis serologies

A None required
Ongoing (unless the patient has
monitoring liver disease or

unmanaged triglycerides)

Seta (derovactin),Prescbing formation tpv accedan gout docs 1496830000 A
2 Shohi otal Orge moto ASS pps PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView

46. Coordinated Interprofessional Care in Psoriasi:

Providers can initiate the following efforts to build or improve on
a coordinated care model for psoriatic conditions in their practices

Implement care pathways that involve routine comorbidity screenings,
personalized patient education, and support with necessary patient behavior changes

For underserved or lower-income populations, offer resources such as counseling on available
services for medication affordability and telehealth capabilities to address care-access
challenges for remote patients or those without adequate transportation for appointments

eerView

Copyright © 2000-2025, Peerview

47. Conclusions

+ Advances in psoriasis pathogenesis have led to effective therapies, including biologics
(TNFa, IL-17, IL-23) and oral agents (PDE4, TYK2 inhibitors)

+ Aneed remains for safe, effective, and convenient oral treatments for PsO and PsA

+ TYK2 is a key mediator in cytokine signaling (IL-12, IL-23, type 1 IFNs) driving PsO and

PsA inflammation

Deucravacitinib is a first-in-class, oral allosteric TYK2 inhibitor approved by the FDA

in 2022 for the treatment of PsO, and is currently under review for PsA.

+ Deucravacitinib had superior efficacy to apremilast and a favorable safety profile in
phase 3 trials

+ Emerging TYK2 inhibitors (eg, zasocitinib, ESK-001) show promise in phase 2 trials,
potentially expanding oral options

+ Apersonalized and team-based approach to care is vital to align treatment with
individual needs

PeerView

PeerView.com/SMF827 Copyright © 2000-2025, PeerView